缅北禁地

Eisai's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji.

Toyoji leaves his village at age 15, heading west to find employment in Osaka.

Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping.

Toyoji leaves Winkel Shokai on being drafted into the Japanese Imperial Guard.

After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe.

World War I begins.

Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation).

Toyoji embarks on a seven-month business tour of India and Southeast Asia.

World War I ends.

Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl.

The Great Kanto Earthquake strikes.

Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake.

Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. A Japanese word Toyoji coins for "high blood pressure" in his Animasa ad campaign enters the Japanese lexicon and remains a general medical term today.

A Salomethyl newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of 缅北禁地paper Advertising.

Tanabe Motosaburo Store Co., Ltd. launches vitamin A product Haliva (halibut liver oil tablets).

Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo.

Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.

The company changes its name from Nihon 缅北禁地. to 缅北禁地., as it is known today.

Eisai rolls out its first three-year mid-term plan.

Eisai's Head Office building is completed in Tokyo.

Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan.

Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges.

Gastrointestinal remedies Saclon and Saclon Tablets, recognizable for their distinct green hue even today, are launched in Japan.

Naturally derived vitamin E product Juvelux is launched in Japan.

Eisai's founder Toyoji Naito passes away at age 89.

Peripheral neuropathy treatment Methycobal is launched in Japan.

Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.

The second oil crisis erupts due to the Iranian Revolution.

Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States.

The Misato Plant commences pharmaceutical manufacturing in Saitama.

The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.

Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).

Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.

Eisai adopts the “Company with Committees” system.

Eisai Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom.

Eisai Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.

Eisai S.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy.

Eisai Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland.

The Corporate Mission is added to the Eisai Articles of Incorporation.

Eisai AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden.

Honorary chairman and Eisai's second president Yuji Naito passes away at age 85.

Eisai Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia.

Eisai rolls out its fifth mid-term plan, the “Dramatic Leap Plan.”

Eisai (Singapore) Pte. Ltd. and Eisai Clinical Research Singapore Pte. Ltd. are established as a pharmaceutical sales subsidiary and clinical research subsidiary, respectively, in Singapore.

Eisai acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.

EF-Eisai Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.

Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.

Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.

Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.

Eisai SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.

Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.

Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.

Rheumatoid arthritis treatment Humira is launched in Japan.

Eisai GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.

The European Knowledge Centre opens as a European strategic base in Hertfordshire, the United Kingdom.

The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.

Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.

The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.

The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.

Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.

Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.

Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.

Anticancer agent Halaven is launched in the United States.

Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.

H3 Biomedicine Inc. is established as a research subsidiary in the United States.

The Great East Japan Earthquake strikes.

Eisai rolls out its sixth mid-term plan, “HAYABUSA.”

Eisai Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.

Halaven is launched in Europe and Japan.

Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.

Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.

Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).

Antiepileptic agent Fycompa is launched in Europe.

Limited Liability Company Eisai is established as a pharmaceutical sales subsidiary in Moscow, Russia.

Eisai co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world.

Eisai initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.

Fycompa is launched in the United States.

Eisai China Holdings Ltd. is established as a holding company in Suzhou, China.

Anticancer agent Lenvima is launched in the United States, Japan and Europe.

Eisai completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Eisai (Liaoning) Pharmaceutical Co., Ltd.)

Eisai rolls out its seventh mid-term plan “EWAY2025.”

EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company.

Fycompa is launched in Japan.

Eisai joins global partnership to address non-communicable diseases.

Eisai pledges continued support for lymphatic filariasis elimination.

Eisai commits funding to the 2nd phase of Global Health Innovative Technology Fund activities.

Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.

Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A.

New Suzhou plant in China commences full-scale operation.

Lenvima (hepatocellular carcinoma) is launched in China.

Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.

Parkinson’s disease treatment Equfina is launched in Japan.

Fycompa and Halaven are launched in China.

The WHO Declares COVID-19 a Pandemic.

“NouKNOW” (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan.

DAYVIGO (insomnia treatment) is launched in the United States and Japan.

Eisai Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam.

Unlimit Health Limited is established in Shanghai, China.

Eisai rolls out its eighth medium-term business plan "EWAY Future 锛咮eyond".

Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States.

Eisai enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202.

The Tokyo Olympics take place.

Eisai Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.

Eisai celebrates its 80th anniversary.

Eisai and Biogen amend collaboration agreements on ADUHELM.

Eisai makes Arteryex Inc., a company that plans and develops software, its subsidiary.

Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.

Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.

Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.

Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.

Eisai commits funding to the 3rd phase of Global Health Innovative Technology Fund.

LEQEMBI is granted traditional approval by the FDA.

Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.

LEQEMBI is launched in Japan.